Friedelin for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Friedelin may be beneficial for
COVID-19 according to the studies below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed Friedelin in detail.
, Studi in silico: Screening Virtual Senyawa Triterpenoid pada Canophyllum inophyllum Sebagai Kandidat Inhibitor SARS-CoV-2, Jurnal Fisika Unand, doi:10.25077/jfu.14.5.459-465.2025
Penelitian ini bertujuan untuk mengidentifikasi potensi senyawa-senyawa triterpenoid dari tamanu (Canophyllum inophyllum) sebagai inhibitor SARS-CoV-2 melalui pendekatan in-silico menggunakan molecular docking. Dipilih sepuluh senyawa triterpenoid dan diuji afinitas ikatannya terhadap main protease (Mpro) SARS-CoV-2 (PDB ID:6W63). Hasil menunjukkan bahwa empat senyawa triterpenoid, diantaranya oleanolic acid (-8.2 kcal/mol), friedelin (-8.2 kcal/mol), inophynone (-8.1 kcal/mol), dan epifriedelanol (-8.2 kcal/mol) memiliki binding affinity yang lebih rendah dibandingkan ligand alami (X77 -8.0 kcal/mol) maupun ligand pembandingnya (paxlovid), yang mengindikasikan interaksi yang lebih kuat terhadap situs aktif protein. Diantara empat kandidat, hanya oleanolic acid yang membentuk ikatan hidrogen dengan residu asam amino pada situs aktif protein, yang memperkuat kemungkinan peranannya sebagai inhibitor SARS-CoV-2. Temuan ini menunjukkan bahwa senyawa-senyawa tersebut, khususnya oleanolic acid, berpotensi dikembangkan lebih lanjut sebagai terapi Covid-19 berbasis bahan alam. Studi ini memberikan kontribusi awal dalam ekplorasi bahan alam sebagai sumber senyawa aktif untuk pengembangan terapi Covid-19 melalui pendekatan in-silico
, SARS-CoV-2 main protease inhibitors from the stem barks of Discoglypremna caloneura (Pax) Prain (Euphorbiaceae) and Pterocarpus erinaceus Poir (Fabaceae) and their molecular docking investigation, Applied Biological Chemistry, doi:10.1186/s13765-023-00833-y
AbstractThe main viral protease (Mpro) of SARS-CoV-2 provides an excellent target for antivirals, due to its essential and conserved function in the viral replication cycle. We reported in this study, the SARS-CoV-2 main protease inhibitory effect of twelve compounds isolated from D. caloneura and P. erinaceus together with four derivatives. Among the effectively tested samples, two derivatized compounds displayed significant improvement on the activity from the starting material, friedelin (1) through the acetoreduced (2) to the acetoxy product (3) with respective IC50 values of 42.89, 29.69 and 19.39 µg/mL. The latter displayed the highest activity although lower as compared to that of baicalein, the positive control with IC50 0.41 µg/mL. The molecular docking study showed that an increase in the number of hydrogen bonds between compounds and active site of Mpro resulted in increased inhibition. Graphical Abstract